Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular acce ...

Simcere Pharmaceuticals Group Ltd. recently announced that findings from the TASTE-2 clinical study have shown that the admini ...

Healionics Corporation announced that its Stargraft arteriovenous (AV) graft for dialysis access has been granted ...

Arsenal Medical announced the initiation of the EMBO-02 clinical study of its NeoCast liquid embolic to treat chronic ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the compa ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

November 5, 2024—In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that patients most affected by the disease were represented.

November 5, 2024—The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the Detour System (Endologix) for the treatment of complex ...

November 5, 2024—Data from the STRIDE study suggest that race, not sex, is associated with outcomes in acute limb ischemia (ALI) treated with mechanical aspiration thrombectomy. Alex Powell, MD, ...